Search

Displaying all 2 results
DrugBest match

Dacomitinib

go.drugbank.com/drugs/DB11963
ApprovedInvestigational

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was de...

  1. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type